<DOC>
	<DOCNO>NCT00002669</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . It yet know treatment regimen effective treat melanoma . PURPOSE : Randomized phase II trial compare effectiveness two regimen combination chemotherapy plus interferon alfa interleukin-2 treating patient metastatic melanoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Interferon Alfa , Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess rate disease stabilization patient metastatic melanoma treat interferon alfa , dacarbazine , cisplatin , interleukin-2 . - Assess toxicity , overall response rate , response duration patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord center . Patients randomize one two treatment arm . - Arm I : Patients receive dacarbazine IV 1 hour cisplatin IV 3 hour day 1-3 . Patients also receive interferon alfa subcutaneously ( SQ ) day 1-5 interleukin-2 continuous IV infusion day 4-9 . Treatment continue every 28 day maximum 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive dacarbazine IV day 1 22 every 28 day 2 course . Patients receive treatment arm I maximum 4 course . Patients follow every 2 month 6 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 42-90 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma metastatic unresectable Measurable , progressive disease ( physical exam and/or noninvasive imaging ) No prior irradiation indicator lesions No CNS metastasis ( confirm CT MRI ) PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Karnofsky 60100 % Life expectancy : Greater 3 month Hematopoietic : WBC least 2,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : No serious hepatic disease Renal : Creatinine great 1.65 mg/dL No serious renal disease Cardiovascular : No serious cardiac disease Pulmonary : No serious pulmonary disease Other : No organ allograft No autoimmune disease No uncontrolled infection No active peptic ulcer No hyper hypothyroidism No requirement corticosteroids No second malignancy except basal cell skin carcinoma carcinoma situ cervix Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy interleukin2 No prior interferon alfa combination cisplatin dacarbazine Chemotherapy : No prior chemotherapy cisplatin combination dacarbazine More 3 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>